MX2020003593A - Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. - Google Patents

Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.

Info

Publication number
MX2020003593A
MX2020003593A MX2020003593A MX2020003593A MX2020003593A MX 2020003593 A MX2020003593 A MX 2020003593A MX 2020003593 A MX2020003593 A MX 2020003593A MX 2020003593 A MX2020003593 A MX 2020003593A MX 2020003593 A MX2020003593 A MX 2020003593A
Authority
MX
Mexico
Prior art keywords
methods
same
neurodegenerative disorders
treating neurodegenerative
benzothiazol
Prior art date
Application number
MX2020003593A
Other languages
English (en)
Inventor
Minwoo Lee
Misoon Kim
Jinhwa Lee
Suyeon Jo
A Yeong Park
Gwibin Lee
Jae Eun Kim
Gyooseung Jung
Seung Mook Lim
Keonseung Lim
Heekyoung Yang
Hyonam Kim
Hyeongjun Kim
Wanjun Li
Mingzhu Fan
Original Assignee
1St Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1St Biotherapeutics Inc filed Critical 1St Biotherapeutics Inc
Publication of MX2020003593A publication Critical patent/MX2020003593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Abstract

La presente divulgación proporciona un compuesto de la Fórmula general (I) que tiene actividad inhibidora de c-abl cinasa o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que comprende el compuesto, y un método útil para tratar o prevenir enfermedades neurodegenerativas usando el compuesto.
MX2020003593A 2017-10-02 2018-10-01 Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. MX2020003593A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762566649P 2017-10-02 2017-10-02
US201862666800P 2018-05-04 2018-05-04
US201862696432P 2018-07-11 2018-07-11
PCT/KR2018/011660 WO2019070093A1 (en) 2017-10-02 2018-10-01 BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

Publications (1)

Publication Number Publication Date
MX2020003593A true MX2020003593A (es) 2020-07-22

Family

ID=65897719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003593A MX2020003593A (es) 2017-10-02 2018-10-01 Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.

Country Status (15)

Country Link
US (2) US10669246B2 (es)
EP (1) EP3692023B1 (es)
JP (2) JP2020536116A (es)
KR (1) KR20200051832A (es)
CN (1) CN111315727B (es)
AU (1) AU2018346051B2 (es)
CA (1) CA3078173A1 (es)
ES (1) ES2953025T3 (es)
FI (1) FI3692023T3 (es)
HU (1) HUE062526T2 (es)
IL (1) IL273705B2 (es)
MX (1) MX2020003593A (es)
PL (1) PL3692023T3 (es)
PT (1) PT3692023T (es)
WO (1) WO2019070093A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062526T2 (hu) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzotiazol vegyületek és azokat alkalmazó eljárások neurodegeneratív rendellenességek kezelésére
CN113454082A (zh) 2019-02-22 2021-09-28 第一生物治疗股份有限公司 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途
US10385046B1 (en) * 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
CN113631554A (zh) * 2019-03-28 2021-11-09 第一生物治疗股份有限公司 苯并噻唑化合物的药用盐、多晶型物及其制备方法
CN110483402B (zh) * 2019-08-12 2021-07-23 上海毕得医药科技股份有限公司 一种3-溴-5-苯基-1h-吡唑的合成方法
EP4200269A1 (en) * 2020-08-21 2023-06-28 1st Biotherapeutics, Inc. [ 18F]-LABELED IMIDAZOPYRIDINE DERIVATIVES AS PET RADIOTRACER

US20230339978A1 (en) * 2020-08-21 2023-10-26 1ST Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
AU2021347913A1 (en) * 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
AU2020471055B8 (en) * 2020-09-30 2023-12-21 Asahi Kasei Pharma Corporation Pyrimidine- and nitrogen-containing bicyclic compound
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1187453A (en) * 1915-09-20 1916-06-13 Allis Chalmers Mfg Co Steam-turbine.
US2258671A (en) * 1940-01-27 1941-10-14 Nat Oil Prod Co Refining of fat-soluble vitamincontaining materials
ES2256969T3 (es) * 1997-11-10 2006-07-16 Bristol-Myers Squibb Company Compuestos de benzotiazol inhibidores de proteina tirosina qauinasa.
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
CA2730106A1 (en) * 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
JP4528849B2 (ja) * 2008-07-14 2010-08-25 シャープ株式会社 引出し型加熱調理器
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
WO2012080284A2 (en) * 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
KR20140107153A (ko) 2014-07-23 2014-09-04 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
HUE062526T2 (hu) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzotiazol vegyületek és azokat alkalmazó eljárások neurodegeneratív rendellenességek kezelésére

Also Published As

Publication number Publication date
US20200270222A1 (en) 2020-08-27
US10968188B2 (en) 2021-04-06
FI3692023T3 (fi) 2023-08-17
HUE062526T2 (hu) 2023-11-28
IL273705B (en) 2022-10-01
AU2018346051A1 (en) 2020-04-09
PT3692023T (pt) 2023-08-23
EP3692023B1 (en) 2023-05-17
IL273705A (en) 2020-05-31
EP3692023A4 (en) 2021-04-07
WO2019070093A1 (en) 2019-04-11
EP3692023A1 (en) 2020-08-12
KR20200051832A (ko) 2020-05-13
JP2023109868A (ja) 2023-08-08
CN111315727A (zh) 2020-06-19
CN111315727B (zh) 2023-09-29
AU2018346051B2 (en) 2022-11-10
PL3692023T3 (pl) 2023-12-11
ES2953025T3 (es) 2023-11-07
RU2020112784A3 (es) 2022-03-05
IL273705B2 (en) 2023-02-01
US20190100500A1 (en) 2019-04-04
RU2020112784A (ru) 2021-11-09
CA3078173A1 (en) 2019-04-11
JP2020536116A (ja) 2020-12-10
US10669246B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
EP3746135A4 (en) METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
IL271085A (en) Bacteria to treat disorders
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MD3600363T2 (ro) Compoziții cuprinzând tulpini bacteriene
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
IL281052A (en) Treatment of liver disorders
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
IL280424A (en) Methods for treating neurodegenerative disorders
PL3774245T3 (pl) Sposób nasypywania
MX2017003728A (es) Sistema mejorador de sabor.
IL262221A (en) Treat ments forcahcers etc
EP3592709A4 (en) METHOD FOR TREATMENT OF WASTE WATER